IO Biotech Shares Surge on Renewed Regulatory Prospects
19.11.2025 - 15:47:05 | boerse-global.de
IO Biotech witnessed a dramatic single-day surge of more than 25% in its share price yesterday. This powerful rally was fueled by the company’s latest quarterly financial report and significant progress in the regulatory pathway for its cancer vaccine candidate, Cylembio.
A pivotal development driving investor sentiment is the scheduled meeting with the U.S. Food and Drug Administration (FDA) in December 2025. This meeting is set to finalize the design for a new Phase 3 clinical trial for Cylembio. The event represents a critical step forward, coming just months after the FDA had previously advised against a regulatory filing for the drug, a move that had triggered a significant stock decline and Read more...
Hol dir jetzt den Wissensvorsprung der Aktien-Profis.
Seit 2005 liefert der Börsenbrief trading-notes verlässliche Aktien-Empfehlungen - Dreimal die Woche, direkt ins Postfach. 100% kostenlos. 100% Expertenwissen. Trage einfach deine E-Mail Adresse ein und verpasse ab heute keine Top-Chance mehr. Jetzt abonnieren.
Für. Immer. Kostenlos.
